Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1139 in moderate-to-severe plaque psoriasis
NCT06875934Phase 2Active, not recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2025
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1139 in plaque psoriasis, sponsored by Hengrui Therapeutics. Started Mar 2025; status: active, not recruiting.
02
Drugs
SHR-1139
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06875934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06875934.